Asahi Kasei Pharma Corporation
June 17, 2025
Company Presentation
Immunology
Asahi Kasei is strengthening its global presence in the pharmaceutical sector through strategic acquisitions and investments. In 2020, Asahi Kasei acquired Veloxis, a US company focusing on solid organ transplantation, and in 2024, it acquired Calliditas, a Swedish company specializing in renal and rare diseases. These investments are driving the global growth of our pharmaceutical business.
Under the “One Pharma” initiative, Asahi Kasei Pharma and its new partners aim to become a leading specialty pharma in immunology, nephrology, and transplantation. This integration enables us to leverage synergies across its global operations and deliver innovative therapeutic solutions to patients worldwide.
Asahi Kasei remains committed to growth of its pharmaceutical business through M&A, licensing, and strategic investments. Especially, licensing of late-stage assets is one of key pillars of our growth strategy. We will continue to seek partnerships that align with our long-term goals.
Company HQ City:
Chiyoda-ku
Company HQ State:
Tokyo
Company HQ Country:
Japan
Year Founded:
1920
Lead Product in Development:
apraglutide
CEO
Yoshikazu Aoki
Development Phase of Lead Product
Multiple Products in Market
Number of Unlicensed Products Looking for Licensing
-
Exchange
TYO
Ticker
3407
When you expect your next catalyst update?
-
What is your next catalyst (value inflection) update?
-
Primary Speaker
Executive Officer, Global Pharmaceuticals Business Development
Asahi Kasei Pharma Corporation
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}